Bruce Cozadd Insider Trade for 1,000 Shares of Jazz Pharmaceuticals plc (JAZZ); Greene County Bancorp (GCBC)’s Sentiment Is 5

March 14, 2018 - By Darrin Black

Greene County Bancorp, Inc. operates as a holding firm for The Bank of Greene County that provides various financial services. The company has market cap of $310.32 million. The Company’s deposit products include savings, NOW accounts, money market accounts, certificates of deposit and non-interest bearing checking accounts, and individual retirement accounts. It has a 24.3 P/E ratio. The companyÂ’s loan portfolio consists of residential, construction and land, and multifamily mortgage loans; commercial real estate mortgage loans; consumer loans, such as loans on new and used automobiles, personal loans, and home equity loans, as well as other consumer installment loans, including passbook loans, unsecured home improvement loans, recreational vehicle loans, and deposit account overdrafts; and commercial loans.

The Chairman & CEO of Jazz Pharmaceuticals Plc, Bruce Cozadd, has just sold – 1,000 shares of the firm he’s managing and operating – coming to a total transaction of $150,000 U.S Dollars (this based on avg share price of $150.0). The date of trade was March 13, 2018, and it was made public in a SEC-filed filing, which you can access here. The regulatory filing shows that Bruce Cozadd now owns exactly 0.49% of the Ireland-based company’s market capitalization (total value of the shares outstanding)

Among 22 analysts covering Jazz Pharmaceuticals (NASDAQ:JAZZ), 17 have Buy rating, 0 Sell and 5 Hold. Therefore 77% are positive. Jazz Pharmaceuticals has $229 highest and $124 lowest target. $180.32’s average target is 19.43% above currents $150.98 stock price. Jazz Pharmaceuticals had 75 analyst reports since August 3, 2015 according to SRatingsIntel. The rating was maintained by BMO Capital Markets with “Buy” on Thursday, January 11. The firm has “Buy” rating by Cantor Fitzgerald given on Thursday, July 27. As per Monday, April 25, the company rating was upgraded by SunTrust. The company was maintained on Wednesday, November 8 by Wells Fargo. On Thursday, August 11 the stock rating was maintained by Deutsche Bank with “Buy”. RBC Capital Markets maintained it with “Buy” rating and $21000 target in Tuesday, June 27 report. The firm has “Neutral” rating by Mizuho given on Tuesday, November 10. Stifel Nicolaus maintained the shares of JAZZ in report on Wednesday, February 24 with “Buy” rating. UBS maintained the shares of JAZZ in report on Wednesday, May 11 with “Buy” rating. FBR Capital maintained the shares of JAZZ in report on Tuesday, December 5 with “Buy” rating.

Jazz Pharmaceuticals Public Limited Company, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has market cap of $9.03 billion. The firm has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. It has a 18.97 P/E ratio. It markets Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia (ALL); Defitelio for the treatment and prevention of severe hepatic veno-occlusive disease, a potentially life-threatening complication of hematopoietic stem cell transplantation; and Prialt, an intrathecally administered infusion of ziconotide for the management of severe chronic pain.

Since October 2, 2017, it had 0 buys, and 11 selling transactions for $2.88 million activity. On Monday, February 26 Young Matthew P. sold $460,381 worth of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) or 3,135 shares. COZADD BRUCE C sold 3,000 shares worth $450,000. 594 shares were sold by Treacy Paul, worth $84,030. Shares for $27,998 were sold by MILLER MICHAEL PATRICK. On Monday, December 11 ENRIGHT PATRICK G sold $1.26M worth of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) or 9,000 shares.

Analysts await Jazz Pharmaceuticals plc (NASDAQ:JAZZ) to report earnings on May, 8. They expect $2.30 earnings per share, up 63.12% or $0.89 from last year’s $1.41 per share. JAZZ’s profit will be $137.55M for 16.41 P/E if the $2.30 EPS becomes a reality. After $2.58 actual earnings per share reported by Jazz Pharmaceuticals plc for the previous quarter, Wall Street now forecasts -10.85% negative EPS growth.

Investors sentiment increased to 1.09 in 2017 Q3. Its up 0.06, from 1.03 in 2017Q2. It increased, as 39 investors sold Jazz Pharmaceuticals plc shares while 82 reduced holdings. 31 funds opened positions while 94 raised stakes. 53.58 million shares or 3.54% more from 51.74 million shares in 2017Q2 were reported. Panagora Asset Management owns 0% invested in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) for 920 shares. 650,923 are held by Citadel Advsrs Ltd Liability. Strs Ohio holds 250,800 shares. Contravisory Investment Management Incorporated holds 28,807 shares or 1.5% of its portfolio. Schroder Management Gru invested in 354,900 shares or 0.09% of the stock. Whittier Commerce invested in 10 shares. Asset One Ltd, Japan-based fund reported 90,988 shares. California Public Employees Retirement System has 0.03% invested in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) for 122,201 shares. Glg Ltd Limited Liability Company stated it has 3,133 shares. Parametric Port Assoc Limited Liability holds 0.01% of its portfolio in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) for 33,956 shares. Schwab Charles Inv Mgmt holds 0.03% of its portfolio in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) for 197,094 shares. Tekla Cap Ltd Company, Massachusetts-based fund reported 273,916 shares. First Personal Financial Services has 0% invested in Jazz Pharmaceuticals plc (NASDAQ:JAZZ). Ardsley Advisory Partners has invested 1.5% in Jazz Pharmaceuticals plc (NASDAQ:JAZZ). 360 are held by Alphaone Svcs Ltd Liability Corporation.

The stock decreased 1.96% or $3.02 during the last trading session, reaching $150.98. About 347,263 shares traded. Jazz Pharmaceuticals plc (NASDAQ:JAZZ) has risen 1.25% since March 14, 2017 and is uptrending. It has underperformed by 15.45% the S&P500.

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: